NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinson’s disease and central nervous system (CNS) disorders through proprietary reformulations of its existing drugs. The company’s liquid formulation of levodopa/carbidopa product candidates includes ND0612L, intended for moderate Parkinson’s diseases; and ND0612H, for severe Parkinson’s disease. It also develops ND0701, intended for patients with severe Parkinson’s disease and ND0801, a product candidate intended for the treatment of cognitive disorders associated with CNS diseases including attention deficit disorder or attention deficit hyperactivity disorder, schizophrenia, alzheimer’s disease, and other diseases. NeuroDerm is headquartered in Rehovot, Israel.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
Reasons to Buy:
Note: Some sections may be missing if data is unavailable for the company
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company NeuroDerm Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
NeuroDerm Ltd Company Overview
NeuroDerm Ltd, Recent Developments
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Intec Pharma Ltd
- XTL Biopharmaceuticals Ltd
- Neurim Pharmaceuticals Ltd
